StockWatch
·
SOUTH INDIAN BANK · Q2 FY27 · THE VERDICT

NIM Beat, Cost Test: The Real Q2 Story

The bank delivered a NIM surprise (3.33% vs 3.25% guidance) and best-in-class asset quality, raising its forward outlook. But the path to 1.5% ROA depends on executing a cost-to-income compression from 57–58% to 50% that remains ahead of it.

Q2 FY27 resultsSOUTHBANKSOUTH INDIAN BANK LTD.22 Oct 2026 · 6 min read
Reported PAT

₹426.3 Cr

+21.3% YoY; highest quarterly

NIM delivered

3.33%

Beat 3.25% guide; +53 bps YoY

Gross NPA

1.24%

-169 bps YoY; best-in-class

Cost-to-income

57–58%

Target 50%; execution gap

South Indian Bank delivered on margins and asset quality in Q2, beating NIM guidance and posting the highest quarterly profit in its history. Yet the stock fell 0.06% on day 1, signalling the market had already priced the beat. The real story is subtler: the quarter proves execution on NIM expansion, but the path to the 1.5% ROA target requires a cost discipline the bank hasn't yet demonstrated.

The claims that hold up

Management's key earnings-call assertions vs. what the numbers confirm
Claim on the callDeliveredVerdict
Highest quarterly net profit ₹426 Cr, 21% growth YoY₹426.3 Cr PAT, 21.3% YoYSupported
NIM at 3.33%, beat 3.25% guidance3.33% delivered; +8 bps beat vs prior guideSupported
Revenue growth ~16%, deposit/advance growth 19%Revenue 16.1% YoY; deposits 19%, advances 19%Supported
Gross NPA 1.24%, net NPA 0.09%, among lowestGross 1.24% (-169 bps YoY), net 0.09% (-47 bps)Supported
Cost-to-income to compress to 50% from current ~57–58%Still at 57–58%; no near-term compression visiblePartial—execution pending

The operational wins are real: NIM beat reflects genuine repricing (43% of loans EBLR-linked, 25–30% gold repriced at higher rates). Deposit/advance growth at 19% confirms the bank is outpacing market guidance (15–16%). Asset quality—gross NPA 1.24%, net 0.09%—is genuinely best-in-class; provision coverage ratio at 97.84% is conservative, leaving upside if the quality story sustains. But the cost-to-income gap is also genuine. Management acknowledged it candidly on the call: "cost is sticky," expansion is ongoing (11 branches in 2 quarters), and the path to 50% is "income outpacing cost"—not cost control, but growth masking the drag.

What changed on this call

  • NIM guidance raised: 3.25% prior → 3.33% delivered, now targeting 3.40–3.50% forward

  • ROA trajectory accelerated: guiding 1.25–1.30% medium term, 1.5% long term

  • Loan mix shift ongoing: retail rising, corporate declining (40% → 39%); gold +41% YoY

  • Deposit mix & repricing: CASA stable 31%; bulk deposits repricing lower than retail

  • Cost-to-income gap acknowledged; no concrete path to 50% near-term

The NIM beat wasn't a one-off: repricing gains are expected to persist as the Repo rate cycle continues and asset yields reprice. Management is confident (correctly) that deposit cost management—bulk repricing lower than retail—buys time. But the ROA story hinges on what hasn't happened yet: cost-to-income compression from 57–58% to 50%, which would release ~70–80 basis points of leverage.

How the street is positioned

Price action: The stock fell 0.06% on day 1 despite beating NIM guidance and delivering best-in-class asset quality. The rally came later—the stock is now within 0.89% of its all-time high of ₹56.25, and is up 76.98% from its 52-week low of ₹31.5. RSI at 77 signals overbought conditions. Verdict: The market priced the beat in before the announcement; the post-result drift reflects incremental conviction, not surprise.

Institutional positioning: FII ownership stood at 25.39% as of Q1 FY27 filings (+1.18 percentage points from Q4 FY26), with DII at 14.25% (+1.49pp). The Q2 results announcement has just occurred; next quarter's filings will show if this accumulation continues. But the Q1 trend—steady inflow despite a 77% rally from the 52-week low—suggests institutions are convinced the operating leverage narrative is real.

The tension: The day-1 flatness and subsequent rally to ATH, coupled with overbought RSI, signal two things: (1) the beat was largely known, and (2) the market is betting on the leverage story. But at ATH with RSI 77, there is minimal room for error. If cost-to-income doesn't compress materially in Q3–Q4, or if deposit repricing slips, the operating leverage case breaks, and the stock's valuation premium evaporates.

The bull-bear debate

Risks, ranked by how much they matter to a holder

Core risks to the operating leverage thesis

Cost-to-income compression stalls near 57–58%

High

ROA target of 1.5% hinges on cost leverage. If opex growth stays at 10–12% YoY and cost remains sticky, operating leverage becomes multi-year, not near-term. Compresses valuation multiple.

Deposit cost inflation & bulk repricing accelerates

Medium

32% of deposits are bulk. If FCNR(B) window closes or RBI signals eventual rate cuts, repricing turns adverse. NII growth slows if funding cost rises faster than asset repricing.

Corporate segment softens; retail/MSME pivot falters

Medium

Corporate contribution declining (40% to 39%) creates near-term pressure. Gold loans +41% YoY are strong, but competitive intensity in retail/gold could compress yields.

Interest rate cycle reversal (RBI pivots to rate cuts)

Medium

NIM guidance 3.40–3.50% assumes continued Repo/Yield curve hikes. Rate cuts would stop repricing gains and pressure margins, especially if deposit repricing lags asset repricing.

Valuation & sentiment at cycle highs

Low-Medium

Stock at ATH with RSI 77; FII ownership at 25.39% (highest in dataset) means consensus is fully priced in. Any stumble on cost control or NIM sustenance triggers sharp correction.

What to watch next

The four numbers that resolve the debate
  • 1 · Cost-to-income ratio (Q3–Q4 trajectory)

    Will it begin compressing toward 50%, or stay stuck at 57–58%? The answer determines whether operating leverage is a near-term catalyst (compression underway) or multi-year. Watch opex growth; it must moderate to <10% annualized for the ratio to compress.

  • 2 · NIM sustainability above 3.30%

    Delivered 3.33% in Q2; targeting 3.40–3.50% forward. Repricing gains are real, but deposit repricing impact and rate cycle stability matter. Any drop below 3.30% signals the repricing cycle is stalling.

  • 3 · ROA ramp toward 1.25%+

    Q2 delivered ~1.08%. Management targets 1.25–1.30% medium-term. Progress depends on cost control + NPA release. If ROA stays below 1.15% in Q3–Q4, the timeline extends and valuation multiple compresses.

  • 4 · Deposit cost & CASA mix stability

    CASA at 31% is stable; bulk deposits repricing down (cushion intact). Watch quarterly deposit cost growth; any spike above 5–6% YoY would signal wholesale repricing is accelerating and hedging NIM gains.

The single number to track

Cost-to-income ratio. If it compresses visibly in Q3–Q4 (toward 56%, then 55%), the operating leverage narrative is real and the stock's premium is justified. If it stays at 57–58%, the story shifts from near-term expansion to a slow, grinding improvement—profitable, but not a lever. That single metric owns the ROA story from here.

South Indian Bank's Q2 confirmed NIM execution (beat guidance, repricing gains real) and stellar asset quality (1.24% gross NPA, 0.09% net). The market believes in the ROA expansion story; FII conviction at 25.39% ownership and the stock's 77% rally off lows attest to that.

But the stock is priced at all-time highs with RSI 77 overbought. The operating leverage—cost-to-income from 57–58% to 50%—is still ahead, not done. The next two quarters will tell whether management can compress costs while the Repo cycle remains supportive and deposit costs don't slip. That execution test is the only thing between ₹426 Cr as a turning point and ₹426 Cr as a steady-state quarter with leverage deferred.

For new investors, the entry point is unfavorable at current valuations. For holders, the thesis is intact but execution matters. Track the quarterly cost-to-income ratio and NIM; that pair of numbers owns the story from here.

Informational and educational content only. Not investment advice.